Journal
BIOMEDICINES
Volume 10, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10082033
Keywords
PBC; ursodeoxycholic acid (UDCA); obeticholic acid (OCA); fibrates; FXR agonists; PPAR agonists; budesonide
Ask authors/readers for more resources
Ursodeoxycholic acid is the first-line therapy for PBC, but new pharmacological agents are being proposed for UDCA-non-responders. Obeticholic acid and fibrates have shown effectiveness in improving biochemistry alteration and symptoms of PBC. Other new agents with different mechanisms of action are also under clinical evaluation for PBC treatment.
Ursodeoxycholic acid (UDCA) is the first-line therapy used for the treatment of PBC. In recent years, new pharmacological agents have been proposed for PBC therapy to cure UDCA-non-responders. Obeticholic acid (OCA) is registered in many countries for PBC, and fibrates also seem to be effective in ameliorating biochemistry alteration and symptoms typical of PBC. Moreover, a variety of new agents, acting with different mechanisms of action, are under clinical evaluation for PBC treatment, including PPAR agonists, anti-NOX agents, immunomodulators, and mesenchymal stem cell transplantation. Since an insufficient amount of data is currently available about the effect of these novel approaches on robust clinical endpoints, such as transplant-free survival, their clinical approval needs to be supported by the consistent improvement of these parameters. The intensive research in this field will hopefully lead to a novel treatment landscape for PBC in the near future, with innovative therapies based on the combination of multiple agents acting on different pathogenetic mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available